When to Consider Prophylactic Antimigraine Therapy in Children with Migraine
- 22 Downloads
Purpose of review
Headache is not an uncommon complaint in children, and recognition of migraine is increasing in children and adolescents. Treatment options consist of abortive and preventive medications; however, when to start the preventive treatment is not clear in the pediatric population. This article reviews current guidelines and practices to provide a better clinical approach in the management of migraines in children and adolescents.
Currently, the only FDA-approved medical treatment option for preventive therapy in chronic migraine in adolescents is topiramate. However, the Childhood and Adolescent Migraine Prevention Study (CHAMP) did not endorse superiority of topiramate or amitriptyline over placebo.
At this time, there is no clear consensus on when to start preventive therapy in children and adolescents with migraines. The decision is multifactorial and should be initiated after a thorough discussion with the patient and caregiver(s) about related risks and benefits of treatment. Education regarding various modalities of treatment and ensuring compliance is essential to treatment success.
KeywordsChronic migraines Children Adolescents Prophylactic therapy Preventive therapy Headaches International Classification of Headache Disorders
Compliance with Ethical Standards
Conflict of Interest
Mushtaq Qureshi and Ferhad Bashir each declare no potential conflicts of interest. Gregory Esper reports other from NeuroOne, Inc., outside the submitted work.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 16.PedMIDAS Tool Cincinnati Children's Hospital Medical Center. Lipton and Stewart. Children's Hospital Medical Center, 2001Google Scholar
- 21.FDA approves Topamax for migraine prevention in adolescents. J Pain Palliat Care Pharmacother. 2014;28(2):191.Google Scholar
- 22.Abstracts of the 47th Annual Congress of the Canadian Neurological Sciences Federation, June 5–8, 2012, Ottawa, Ontario, Canada. Can J Neurol Sci. 2012;39(3 Suppl 3):S1–54.Google Scholar
- 23.• Powers SW, Coffey CS, Chamberlin LA, Ecklund DJ, Klingner EA, Yankey JW, et al. Trial of amitriptyline, topiramate, and placebo for pediatric migraine. N Engl J Med. 2017;376(2):115–24 Trial demonstrating no significant differences in reduction in headache frequency or headache-related disability in childhood and adolescent migraine with amitryptiline, topiramate, or placebo over a period of 24 weeks.CrossRefGoogle Scholar
- 24.•• Fallah R, Fazelishoroki F, Sekhavat LA. Randomized clinical trial comparing the efficacy of melatonin and amitriptyline in migraine prophylaxis of children. Iran J Child Neurol. 2018;12(1):47–54 Recent randomized controlled trial comparing amitriptiline and melatonin for migraine prophylaxis and considered amitryptiline to be safer but associated with more adverse events.PubMedPubMedCentralGoogle Scholar